Care Transition Intervention for Patients With Cancer

Status Completed

Clinical Trial Summary

This research study is investigating an intervention called CONTINUity of care Under Management by Video visits (CONTINUUM-V). CONTINUUM-V involves a video visit with an oncology nurse practitioner within three business days of hospital discharge for patients with advanced cancer with the goal of reducing burdensome care transitions after hospitalization, including hospital readmissions.

Clinical Trial Description

This is a single-site, single-arm pilot trial to assess the feasibility and acceptability of a CONTINUUM-V for patients with advanced cancer The research study procedures include: - A video visit with a nurse practitioner within three business days of hospital discharge - Questionnaires asking about demographic information (e.g. sex, ethnicity, income) and participant experience with cancer (e.g. symptoms and confidence in managing their health condition) - A satisfaction survey to assess the participants' impressions of the intervention and any suggestions the participants may have - Data collection from their medical record - One time interview of participant and clinician for feedback on CONTINUUM-V Participants will be in this research study for up to 45 days after hospital discharge. 54 patients and 4 clinicians took part in this research study. The Conquer Cancer Foundation and the Rising Tide Foundation for Clinical Cancer Research are supporting this research study by providing a Career Pathway Grant in Symptom Management to support the research team. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04640714
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Completed
Phase	N/A
Start date	January 7, 2021
Completion date	July 14, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03181854` - Randomized Controlled Trial of Integrated Early Palliative Care	N/A
Completed	`NCT01197170` - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance	Phase 1
Recruiting	`NCT05045040` - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions	N/A
Active, not recruiting	`NCT05060432` - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03994601` - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers	Phase 1/Phase 2
Active, not recruiting	`NCT03667716` - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.	Phase 1
Completed	`NCT01393990` - A Study of LY2228820 in Participants With Advanced Cancer	Phase 1
Completed	`NCT02857270` - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer	Phase 1
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Active, not recruiting	`NCT04121676` - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer	Phase 1
Active, not recruiting	`NCT03177291` - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC	Phase 1
Completed	`NCT03980041` - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)	Phase 2
Active, not recruiting	`NCT03674567` - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab	Phase 1/Phase 2
Recruiting	`NCT04823377` - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.	N/A
Completed	`NCT02778126` - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer	Phase 1
Completed	`NCT02529553` - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer	Phase 1
Completed	`NCT02507544` - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer	Phase 1
Completed	`NCT02245204` - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers	Phase 1
Completed	`NCT01583777` - Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer	Phase 1
Terminated	`NCT01929941` - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies	Phase 1